Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging

Nuclear Medicine and Biology

Volumn 38, Issue 7, 2011, Pages 1011-1018

  Suzuki, Kentaro ^a   Satake, Miho ^a   Suwada, Jun ^a   Oshikiri, Shinobu ^a   Ashino, Hiroki ^a   Dozono, Hiroyuki ^a   Hino, Akihiro ^a   Kasahara, Hiroyuki ^a   Minamizawa, Takao ^a  

^a Fujifilm RI Pharma Co Ltd   (Japan)

Author keywords

68Ga; Bisphosphonate; Bone; Bone scintigraphy; Bone seeking agent; PET

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID BISPHOSPHONATE GA 68; 2 [4,7 DI(CARBOXYMETHYL) 1,4,7 TRIZONAN 1 YL] 5 [(4 HYDROXY 4,4 DIPHOSPHONOBUTYL)AMINO] 5 OXOPENTANOIC ACID; 5 [[4 [[1 (TERT BUTYL) 1 ,1 DIMETHYLSILYL]OXY] 4,4 DI(DIETHOXYPHOSPHORYL)BUTYL]AMINO] 2 [4,7 DI[2 (TERT BUTOXY) 2 OXOETHYL] 1,4 7 TRIAZONANE 1 LY] 5 OXOPENTANOATE; HYDROXYAPATITE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BONE BLOOD FLOW; BONE LESION; BONE METASTASIS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RADIOCHEMISTRY; RAT;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; CELL LINE, TUMOR; CHELATING AGENTS; DIPHOSPHONATES; DURAPATITE; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MICE; OSTEOLYSIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RATS; REPRODUCIBILITY OF RESULTS;

EID: 80053578346     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.02.015     Document Type: Article

References (31)

1. Coleman R.E. Skeletal complications of malignancy. Cancer 1997, 80:1588-1594.
2. Coleman R.E. Bisphosphonates: clinical experience. Oncologist 2004, 9(Suppl 4):14-27.
3. Love C., Din A.S., Tomas M.B., Kalapparambath T.P., Palestro C.J. Radionuclide bone imaging: an illustrative review. Radiographics 2003, 23:341-358.
4. Subramanian G., McAfee J.G., Blair R.J., Kallfelz F.A., Thomas F.D. Technetium-99m-methylene diphosphonate - a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med 1975, 16:744-755.
5. Abe K., Sasaki M., Kuwabara Y., Koga H., Baba S., Hayashi K., et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005, 19:573-579.
6. Even-Sapir E., Metser U., Mishani E., Lievshitz G., Lerman H., Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006, 47:287-297.
7. Hetzel M., Arslandemir C., Konig H.H., Buck A.K., Nussle K., Glatting G., et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res 2003, 18:2206-2214.
8. Schirrmeister H., Glatting G., Hetzel J., Nussle K., Arslandemir C., Buck A.K., et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001, 42:1800-1804.
9. Schirrmeister H., Guhlmann A., Kotzerke J., Santjohanser C., Kuhn T., Kreienberg R., et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999, 17:2381-2389.
10. Kruger S., Buck A.K., Mottaghy F.M., Hasenkamp E., Pauls S., Schumann C., et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009, 36:1807-1812.
11. Schirrmeister H., Guhlmann A., Elsner K., Kotzerke J., Glatting G., Rentschler M., et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999, 40:1623-1629.
12. Gleason G.I. A positron cow. Int J Appl Radiat Isot 1960, 8:90-94.
13. Greene M.W., Tucker W.D. An improved gallium-68 cow. Int J Appl Radiat Isot 1961, 12:62-63.
14. Breeman W.A., Verbruggen A.M. The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?. Eur J Nucl Med Mol Imaging 2007, 34:978-981.
15. Fani M., Andre J.P., Maecke H.R. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging 2008, 3:67-77.
16. Hayes R.L., Carlton J.E., Byrd B.L. Bone scanning with gallium-68: a carrier effect. J Nucl Med 1965, 6:605-610.
17. Goulet R.T., Shysh A., Noujaim A.A. Investigation of 68Ga-tripolyphosphate as a potential bone-scanning agent. Int J Appl Radiat Isot 1975, 26:195-199.
18. Dewanjee M.K., Hnatowich D.J., Beh R. New 68Ga-labeled skeletal-imaging agents for positron scintigraphy. J Nucl Med 1976, 17:1003-1007.
19. Toegel S., Wadsak W., Mien L.K., Viernstein H., Kluger R., Eidherr H., et al. Preparation and pre-vivo evaluation of no-carrier-added, carrier-added and cross-complexed [68Ga]-EDTMP formulations. Eur J Pharm Biopharm 2008, 68:406-412.
20. Mitterhauser M., Toegel S., Wadsak W., Lanzenberger R.R., Mien L.K., Kuntner C., et al. Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP. Nucl Med Biol 2007, 34:391-397.
21. Zhang S., Gangal G., Uludag H. 'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents. Chem Soc Rev 2007, 36:507-531.
22. Eisenwiener K.P., Prata M.I., Buschmann I., Zhang H.W., Santos A.C., Wenger S., et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002, 13:530-541.
23. Eisenwiener K.P., Powell P., Macke H.R. A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling. Bioorg Med Chem Lett 2000, 10:2133-2135.
24. Vachal P., Hale J.J., Lu Z., Streckfuss E.C., Mills S.G., MacCoss M., et al. Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis. J Med Chem 2006, 49:3060-3063.
25. Fizazi K., Yang J., Peleg S., Sikes C.R., Kreimann E.L., Daliani D., et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 2003, 9:2587-2597.
26. Miwa S., Mizokami A., Keller E.T., Taichman R., Zhang J., Namiki M. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res 2005, 65:8818-8825.
27. Yang J., Fizazi K., Peleg S., Sikes C.R., Raymond A.K., Jamal N., et al. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 2001, 61:5652-5659.
28. Ferreira C.L., Lamsa E., Woods M., Duan Y., Fernando P., Bensimon C., et al. Evaluation of bifunctional chelates for the development of gallium-based radiopharmaceuticals. Bioconjug Chem 2010, 21:531-536.
29. Velikyan I., Maecke H., Langstrom B. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjug Chem 2008, 19:569-573.
30. Disselhorst J.A., Brom M., Laverman P., Slump C.H., Boerman O.C., Oyen W.J., et al. Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner. J Nucl Med 2010, 51:610-617.
31. Fellner M., Baum R.P., Kubicek V., Hermann P., Lukes I., Prasad V., et al. PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging 2010, 37:834.